Stereotactic body radiotherapy for oligometastases confined to the para-Aortic region: Clinical outcomes and the significance of radiotherapy field and dose

Cancer Investigation

Volumn 33, Issue 5, 2015, Pages 180-187

  Seo, Young Seok ^a   Kim, Mi Sook ^a   Cho, Chul Koo ^a   Yoo, Hyung Jun ^a   Jang, Won Il ^a   Kim, Kum Bae ^a   Lee, Dong Han ^a   Moon, Sun Mi ^a   Lee, Hoy Rak ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Outcomes research; Prognosis and response predictions; Radiation oncology

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RETROSPECTIVE STUDY; SARCOMA; SKIN CANCER; SMALL INTESTINE OBSTRUCTION; STEREOTACTIC BODY RADIATION THERAPY; STOMACH CANCER; VAGINA CANCER; AGED; METASTASIS; NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84929878972     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2015.1019678     Document Type: Article

References (43)

1. Wilkins EW, Jr, Burke JF, Head JM. The surgical management of metastatic neoplasms in the lung. J Thorac Cardiovasc Surg. 1961 Sep;42:298-309.
2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011 Jun;8(6):378-82.
3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8-10.
4. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004 Jan;91(1):112-20.
5. Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, Yokouchi H. Surgery for pulmonary metastases from colorectal cancer:The importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Jpn J Thorac Cardiovasc Surg. 2003 Jul;51(7):289-96.
6. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: A systematic review of published series. AnnThorac Surg. 2007 Jul;84(1):324-38.
7. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgicalmargin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May;241(5):715, 22, discussion 722-4.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309, 18; discussion 318-21.
9. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 1;27(10):1579-84.
10. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, FranklinW, KaneM, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009Apr 1;27(10):1572-8.
11. Bae SH, KimMS, Cho CK, Kang JK, Kang HJ, KimYH, ShinUS, Moon SM, LeeDH. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012 Aug 1;106(2):138-43.
12. Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, Zatcky J, Kim B, Yamada Y. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1151-7.
13. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97.
14. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: Long-Term followup of prospective study. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86.
15. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, WeichselbaumRR. Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 1;118(11):2962-70.
16. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood. 2009 Jul 16;114(3):589-95.
17. HoyerM, RoedH, TrabergHansenA, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823-30.
18. Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, Castiglioni S, Carnaghi C, Tronconi MC, Santoro A, Scorsetti M. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):831-8.
19. Choi CW, Cho CK, Yoo SY, Kim MS, Yang KM, Yoo HJ, Seo YS, Kang JK, Lee DH, Lee KH, Lee ED, Rhu SY, Choi SC, Kim MH, Kim BJ. Image-guided stereotactic body radiation therapy in patients with isolated para-Aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53.
20. Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, Fossati Ing P, Gherardi F, Alterio D, Zerini D, Garibaldi C, Baroni G, De Cobelli O, Orecchia R. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol. 2012 Sep 18.
21. KimMS, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer.World J Gastroenterol. 2009 Dec 28;15(48):6091-5.
22. Kim MS, Yoo SY, Cho CK, Yoo HJ, Yang KM, Kang JK, Lee DH, Lee JI, Bang HY, Kim MS, Kang HJ. Stereotactic body radiotherapy for isolated para-Aortic lymph node recurrence after curative resection in gastric cancer. J KoreanMed Sci. 2009 Jun;24(3):488-92.
23. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011 Jan-Feb;97(1):49-55.
24. Kang JK, KimMS, KimJH, Yoo SY, Cho CK, Yang KM, Yoo HJ, Seo YS, LeeDH, Kang HJ, Kim YH, ShinUS. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010 Apr;27(4):273-8.
25. Cox JD, Stetz J, PajakTF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6.
26. Webb S, NahumAE.Amodel for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 1993 Jun;38(6):653-66.
27. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence:The new era of cancer therapy. Jpn J Clin Oncol. 2010 Feb;40(2):107-11.
28. de Vin T, Engels B, Gevaert T, Storme G, De RidderM. Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival. Ann Oncol. 2014 Feb;25(2):467-71.
29. Yahara K, Ohguri T, Imada H, Yamaguchi S, Terashima H, Korogi Y. Cancer of the pelvis: Definitive three-dimensional conformal radiotherapy for patients with isolated recurrence in the para-Aortic lymph nodes. J Radiat Res. 2012 Sep;53(5): 735-41.
30. Yeo SG, Kim DY, Kim TH, Jung KH, Hong YS, Kim SY, Park JW, Choi HS, Oh JH. Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. Radiother Oncol. 2010 Nov;97(2):307-11.
31. Haddock MG, Nelson H, Donohue JH, Taylor WE, Devine RM, Nagorney DM, Wolff BG, OConnell MJ, Gunderson LL. Intraoperative electron radiotherapy as a component of salvage therapy for patientswith colorectal cancer and advanced nodalmetastases. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):966-73.
32. Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Longterm follow-up of RTOG 92-10: Cervical cancer with positive para-Aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):982-7.
33. Small W, Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K.. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-Aortic or high common iliac lymph nodes: Results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1081-7.
34. Poorvu PD, Sadow CA, Townamchai K, Damato AL, Viswanathan AN. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1262-8.
35. Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, Tseng CJ, Tsai CS, Chang JT. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):442-8.
36. Kim JS, Kim JS, Kim SY, Kim K, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-Aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53.
37. Sun J, SunYH, ZengZC, QinXY, ZengMS, ChenB, LiuTS, Zhang JY. Consideration of the role of radiotherapy for abdominal lymph nodemetastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):384-91.
38. Niibe Y, KenjoM, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, KataokaM, Suzuki K, IiN, Uno T, Takanaka T, Higuchi K, Yamazaki H, Tokumaru S, Oguchi M, Hayakawa K. Multiinstitutional study of radiation therapy for isolated para-Aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5, 000. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1366-9.
39. Townamchai K, Poorvu PD, Damato AL, DeMaria R, Lee LJ, Berlin S, Feltmate C, Viswanathan AN. Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer. Pract Radiat Oncol. 2014Mar- Apr;4(2):90-8.
40. Hill BT. Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro. Cytotechnology. 1993;12(1-3):265-88.
41. TreeAC, Khoo VS, Eeles RA, AhmedM, DearnaleyDP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013 Jan;14(1):e28-37.
42. Seo YS, KimMS, Yoo HJ, Jang WI. Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J Gastroenterol. 2014 Feb 28;20(8):2005-13.
43. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100-7.